Stock IDT IDT AUSTRALIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials IDT Australia Limited

Equities

IDT

AU000000IDT0

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 01:25:10 2024-04-26 am EDT 		5-day change 1st Jan Change
0.095 AUD -2.06% Intraday chart for IDT Australia Limited 0.00% -13.64%
Apr. 16 IDT Australia Signs Master Service Agreement with Sanofi MT
Feb. 21 IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Capitalization 1 23.47 39 39.49 77.95 27.72 23.76
Enterprise Value (EV) 1 9.984 29.51 32.63 71.79 19.38 20.07
P/E ratio -1.39 x -6.5 x -20.4 x 37 x -23 x -1.87 x
Yield - - - - - -
Capitalization / Revenue 1.76 x 3.22 x 2.79 x 4.61 x 2.29 x 3.38 x
EV / Revenue 0.75 x 2.43 x 2.3 x 4.24 x 1.6 x 2.85 x
EV / EBITDA -4.51 x -8.7 x 49.2 x 27.4 x -202 x -2.3 x
EV / FCF 3.81 x -44.2 x -24 x -56.1 x -19 x -2.8 x
FCF Yield 26.3% -2.26% -4.16% -1.78% -5.26% -35.7%
Price to Book 0.72 x 1.56 x 1.69 x 2.82 x 1.03 x 0.82 x
Nbr of stocks (in thousands) 244,467 236,359 239,313 239,860 241,022 365,522
Reference price 2 0.0960 0.1650 0.1650 0.3250 0.1150 0.0650
Announcement Date 8/21/18 8/29/19 8/25/20 8/24/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2018 2019 2020 2021 2022 2023
Net sales 1 13.3 12.13 14.17 16.93 12.13 7.032
EBITDA 1 -2.215 -3.394 0.663 2.618 -0.096 -8.737
EBIT 1 -4.454 -5.565 -1.245 0.966 -1.876 -9.776
Operating Margin -33.49% -45.88% -8.79% 5.71% -15.47% -139.02%
Earnings before Tax (EBT) 1 -18.58 -6.119 -1.981 0.966 -1.876 -9.776
Net income 1 -16.98 -6.083 -1.919 2.103 -1.16 -8.498
Net margin -127.66% -50.15% -13.54% 12.42% -9.56% -120.85%
EPS 2 -0.0690 -0.0254 -0.008093 0.008787 -0.005000 -0.0348
Free Cash Flow 1 2.621 -0.6671 -1.357 -1.279 -1.02 -7.166
FCF margin 19.71% -5.5% -9.58% -7.56% -8.41% -101.91%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/21/18 8/29/19 8/25/20 8/24/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 13.5 9.49 6.86 6.16 8.33 3.69
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 2.62 -0.67 -1.36 -1.28 -1.02 -7.17
ROE (net income / shareholders' equity) -41.7% -21.2% -7.94% 8.26% -4.25% -33.5%
ROA (Net income/ Total Assets) -5.74% -9.92% -2.6% 1.93% -3.65% -20.9%
Assets 1 295.9 61.31 73.73 109.2 31.76 40.59
Book Value Per Share 2 0.1300 0.1100 0.1000 0.1200 0.1100 0.0800
Cash Flow per Share 2 0.0600 0.0400 0.0300 0.0300 0.0400 0.0100
Capex 1 0.92 1.14 0.76 0.53 0.91 0.52
Capex / Sales 6.9% 9.42% 5.37% 3.11% 7.52% 7.42%
Announcement Date 8/21/18 8/29/19 8/25/20 8/24/21 8/30/22 8/28/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IDT AUSTRALIA LIMITED Stock IDT Australia Limited
-13.64% 21.78M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. IDT Stock
  4. Financials IDT Australia Limited